LINCOLN PHARMACEUTICALS LTD.

Lincoln Pharmaceuticals Ltd. is dispatching physical communication, including a web-link to its Annual Report for FY 2025-26, to shareholders who have not registered their email addresses. This action complies with SEBI Listing Regulations. The company is also reminding shareholders to update KYC details and dematerialize physical securities, highlighting that payments like dividends will only be processed electronically for those with incomplete KYC from April 1, 2024. The 32nd Annual General Meeting is scheduled for September 30, 2026, via Video Conferencing.

Lincoln Pharmaceuticals Ltd. has submitted its Annual Report and Notice for the 32nd Annual General Meeting (AGM) for FY 2025-2026. The AGM will be held on Wednesday, September 30, 2026, at 11:00 a.m. IST via Video Conference. Key dates include August 28, 2026, as the cut-off for members entitled to receive the AGM notice and annual report, September 11, 2026, for dividend entitlement, and September 23, 2026, for e-voting. Remote e-voting will commence on September 26, 2025, at 9:00 a.m. IST and conclude on September 29, 2025, at 5:00 p.m. IST. The company's website, www.lincolnpharma.com, and CDSL's e-voting portal (https://www.evotingindia.com/) will host relevant information.

Lincoln Pharmaceuticals Ltd. announced that its 32nd Annual General Meeting (AGM) will be held on Wednesday, September 30, 2026, at 11:00 AM IST. The meeting will be conducted through Video Conferencing (VC) or Other Audio-Visual Means (OAVM). Key agenda items include the adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026, declaration of a dividend of ₹1.80 per equity share, and the re-appointment of two directors, Mr. Hashmukh I. Patel and Mr. Munjal Mahendrabhai Patel, who are retiring by rotation. Additionally, the members will consider ratifying the remuneration of the cost auditors, Kiran J. Mehta & Co., for ₹2,50,000 per annum plus applicable taxes and expenses.

Lincoln Pharmaceuticals Ltd has announced that its 32nd Annual General Meeting (AGM) will be held on Wednesday, September 30, 2026, at 11:00 a.m. IST, conducted via Video Conferencing/Other Audio-Visual Means. The company also informed about the book closure period from Saturday, September 12, 2026, to Wednesday, September 30, 2026. This period is for determining shareholder entitlement for a proposed final dividend of 18%, amounting to ₹1.80 per equity share of ₹10 face value, for the financial year April 1, 2025, to March 31, 2026. The dividend payment is contingent upon approval by the members at the AGM.

Lincoln Pharmaceuticals Ltd announced its un-audited financial results for the quarter ended June 30, 2026. The company's Board of Directors approved the standalone and consolidated results. The results were published in accordance with SEBI Listing Regulations and are available on the company's website. The financial highlights for the quarter were also enclosed with the filing.

Lincoln Pharmaceuticals posted consolidated net profit of ₹36.23 Cr for Q1 FY27 (quarter ended June 30, 2026), up 30.9% YoY from ₹27.68 Cr, on revenue from operations of ₹177.28 Cr, up 15.1% YoY from ₹154.07 Cr. EBITDA rose 32.3% YoY to ₹51.70 Cr. Standalone and consolidated results are identical this quarter — the only subsidiary, Zullinc Healthcare LLP, posted nil revenue and nil loss, so the group print carries no minority-interest or consolidation drag. Basic EPS came in at ₹18.09 against ₹13.82 a year ago. Sequentially, revenue eased 5.3% from a seasonally elevated ₹187.28 Cr in Q4 FY26, and while PAT looks sharply higher QoQ (from ₹11.63 Cr), that's mostly because Q4 carried a rare ₹4.20 Cr net loss on the other-income line that depressed its base — the YoY read is the one that matters here, not the QoQ jump. The margin picture is more nuanced than the headline PAT growth suggests. Core operating profit (EBITDA less other income, over revenue from operations) was ₹27.43 Cr, or about 15.5% of revenue — almost unchanged from 15.45% a year ago — meaning the underlying pharma business grew revenue and core operating profit in near lockstep (~15%), with no real operating leverage showing up yet. The extra lift in PBT (+34.4% YoY to ₹47.55 Cr) and PAT came chiefly from other income, which jumped 58.9% YoY to ₹24.26 Cr from ₹15.27 Cr; the filing gives no breakup of this line, so its recurring nature can't be confirmed. Working against that tailwind, the effective tax rate rose to 23.8% from 21.8% YoY, trimming some of the PBT gain on its way to the bottom line. No exceptional items were reported in either period, so no raw-vs-adjusted PAT split is needed. On guidance, management's press release reiterates a medium-term target of ₹1,000 Cr revenue over three years via 15-18% annual growth, led by cardiac, diabetic, dermatology and ENT segments; our records hold no prior formal guidance to grade this quarter against, and a web search turned up no analyst consensus for the quarter — Lincoln Pharma carries thin sell-side coverage, so the street comparison is marked unknown rather than guessed. Q1's 15.1% YoY revenue growth sits at the low end of that guided band. Director Munjal Patel framed the quarter as "building on our existing growth momentum," citing recent Canada, EU GMP and TGA Australia approvals as the company works to expand its export footprint from 60+ to 90 countries over 2-3 years; the filing does not break out export revenue to check that claim against a number. The company remains net-debt free, with FII holding at 4.60% as of June 30, 2026, and CRISIL reaffirmed its A/Stable/A1 ratings during the quarter.

Lincoln Pharmaceuticals Ltd has announced that its Board of Directors will convene on August 13, 2026, at the company's registered office. The primary agenda items include the consideration and approval of the un-audited financial results (standalone and consolidated) for the quarter ended June 30, 2026. Additionally, the board may discuss any other business with the Chairman's permission. In compliance with SEBI regulations, the trading window for the company's securities has been closed from July 1, 2026, and will reopen 48 hours after the financial results are made public. The company secretary and compliance officer, Trusha Shah, has formally intimated this to BSE.

Lincoln Pharmaceuticals Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will be shut from July 01, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026. All directors, senior management, promoters, and connected persons are advised not to trade during this period. The date for the Board of Directors' meeting to approve these financial results will be communicated separately.

Lincoln Pharmaceuticals Limited's Board of Directors, at its meeting on May 28, 2026, approved the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026. The board also recommended a final dividend of ₹1.80 per equity share, representing 18% of the face value, for the financial year ended March 31, 2026. This dividend recommendation is subject to approval by shareholders at the upcoming Annual General Meeting. For the year ended March 31, 2026, the company reported revenue from operations of ₹67,102.99 Lakhs and a net profit of ₹8,789.38 Lakhs.

Lincoln Pharmaceuticals Limited announced its audited financial results for the quarter and year ended March 31, 2026. For Q4 FY26, the company reported a standalone net profit of ₹11.63 crore on revenue from operations of ₹187.28 crore. For the full fiscal year FY26, standalone net profit stood at ₹87.89 crore, with revenue from operations reaching ₹671.03 crore. The Board of Directors also recommended a dividend of 18% (₹1.80 per share) for the year ended March 31, 2026, subject to approval at the upcoming Annual General Meeting.